Abstract 19227: Weight History Influences the Likelihood of Subclinical Myocardial Injury
Introduction: Obesity is associated with myocardial injury as reflected by levels of high-sensitivity cardiac troponin T (hs-cTnT), and the combination of obesity and elevated hs-cTnT is linked to markedly increased heart failure risk. The association of weight history with myocardial injury is unknown.
Hypothesis: We hypothesized that prior obesity increases the likelihood of myocardial injury among individuals without clinical cardiovascular disease (CVD).
Methods: We evaluated 9,472 participants (mean age 63 years) at ARIC Visit 4 (1996-99) with BMI ≥ 18.5 kg/m2 and without prior CVD. BMI (kg/m2) at Visit 4 and BMI calculated from self-reported weight at age 25 were categorized as normal weight (18.5-24.9), overweight (25-29.9) and obese (≥30). We then cross-tabulated BMI categories at Visit 4 and at age 25. A cumulative weight measure of “BMI years” was also calculated by taking the average of the BMI values at ARIC visits 1-4 and at age 25 (with BMI centered at 25 kg/m2) and multiplying the average by the number of years from age 25 to visit 4. The primary outcome was elevated hs-cTnT (≥14 ng/L) at Visit 4. Logistic regression was used to estimate the associations of cross-categories of BMI at the two time points and of BMI years with elevated hs-cTnT.
Results: Within each Visit 4 BMI category, a higher BMI category at age 25 was associated with increased odds of elevated hs-cTnT, with the highest odds seen among those with obesity at both time points (OR 4.97 [95% CI: 3.39-7.29]) compared to those with normal weight at both time points. BMI years ranged from -307 to 1,205 ((kg/m2) x years). A graded positive association was seen between BMI years and myocardial injury (Figure), with each 100 higher BMI years linked to a 27% higher likelihood of elevated hs-cTnT.
Conclusions: Prior obesity and greater cumulative weight from young adulthood increase the likelihood of subclinical myocardial injury, underscoring the importance of long-term weight control for reducing CVD risk.
Author Disclosures: C. Ndumele: None. L. Cobb: None. M. Lazo: None. N. Bello: None. A. Shah: None. V. Nambi: Other; Modest; Dr. Nambi filed a provisional patent (patent #61721475) entitled “Biomarkers to Improve Prediction of Heart Failure Risk”.. R.S. Blumenthal: None. G. Gerstenblith: None. S.D. Solomon: None. C.M. Ballantyne: Other; Modest; Dr. Ballantyne filed a provisional patent (patent #61721475) entitled “Biomarkers to Improve Prediction of Heart Failure Risk”.. E. Selvin: None. J. Coresh: None.
- © 2015 by American Heart Association, Inc.